RGNX REGENXBIO Inc

Price (delayed)

$18.54

Market cap

$815.61M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.99

Enterprise value

$851.01M

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, ...

Highlights
RGNX's EPS is up by 5% since the previous quarter
The net income is up by 5% from the previous quarter
RGNX's gross profit has dropped by 85% year-on-year but it is up by 5% since the previous quarter
The company's revenue has shrunk by 79% YoY but it rose by 2.5% QoQ
The equity has contracted by 36% YoY and by 11% from the previous quarter
The quick ratio has declined by 23% year-on-year and by 11% since the previous quarter

Key stats

What are the main financial stats of RGNX
Market
Shares outstanding
43.99M
Market cap
$815.61M
Enterprise value
$851.01M
Valuations
Price to book (P/B)
2.24
Price to sales (P/S)
8.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.56
Earnings
Revenue
$99.37M
EBIT
-$250.77M
EBITDA
-$233.66M
Free cash flow
-$231.32M
Per share
EPS
-$5.99
Free cash flow per share
-$5.26
Book value per share
$8.26
Revenue per share
$2.26
TBVPS
$14.42
Balance sheet
Total assets
$633.79M
Total liabilities
$270.69M
Debt
$90.7M
Equity
$363.1M
Working capital
$238.49M
Liquidity
Debt to equity
0.25
Current ratio
2.87
Quick ratio
2.62
Net debt/EBITDA
-0.15
Margins
EBITDA margin
-235.1%
Gross margin
61%
Net margin
-262.2%
Operating margin
-263.6%
Efficiency
Return on assets
-36%
Return on equity
-59.5%
Return on invested capital
-40.4%
Return on capital employed
-49.5%
Return on sales
-252.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RGNX stock price

How has the REGENXBIO stock price performed over time
Intraday
-1.54%
1 week
15.59%
1 month
35.23%
1 year
-16.41%
YTD
3.29%
QTD
3.29%

Financial performance

How have REGENXBIO's revenue and profit performed over time
Revenue
$99.37M
Gross profit
$60.62M
Operating income
-$262M
Net income
-$260.54M
Gross margin
61%
Net margin
-262.2%
RGNX's gross profit has dropped by 85% year-on-year but it is up by 5% since the previous quarter
The company's revenue has shrunk by 79% YoY but it rose by 2.5% QoQ
The gross margin has declined by 29% year-on-year but it has increased by 2.9% since the previous quarter
REGENXBIO's net margin has increased by 7% QoQ

Growth

What is REGENXBIO's growth rate over time

Valuation

What is REGENXBIO stock price valuation
P/E
N/A
P/B
2.24
P/S
8.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.56
RGNX's EPS is up by 5% since the previous quarter
The equity has contracted by 36% YoY and by 11% from the previous quarter
RGNX's P/B is 20% below its 5-year quarterly average of 2.8 but 12% above its last 4 quarters average of 2.0
The company's revenue has shrunk by 79% YoY but it rose by 2.5% QoQ
The price to sales (P/S) is 41% lower than the 5-year quarterly average of 14.0

Efficiency

How efficient is REGENXBIO business performance
RGNX's return on sales is up by 6% since the previous quarter
The ROE is down by 6% QoQ
The ROIC has contracted by 3.6% from the previous quarter
REGENXBIO's ROA has decreased by 3.4% from the previous quarter

Dividends

What is RGNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RGNX.

Financial health

How did REGENXBIO financials performed over time
RGNX's total assets is 134% greater than its total liabilities
RGNX's total assets is down by 28% year-on-year and by 7% since the previous quarter
The quick ratio has declined by 23% year-on-year and by 11% since the previous quarter
REGENXBIO's debt is 75% lower than its equity
RGNX's debt to equity has soared by 56% year-on-year and by 9% since the previous quarter
The equity has contracted by 36% YoY and by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.